Loading...
Market
How many new molecular glue-based projects will Evotec and Bristol Myers Squibb initiate by the end of 2025?
3
Resolution / Starting Odds
1-2 projects • 25%
3-4 projects • 25%
5-6 projects • 25%
More than 6 projects • 25%
Official announcements from Evotec or Bristol Myers Squibb
Story
Evotec and Bristol Myers Squibb Expand Proteomics Partnership with $50 Million Upfront
Oct 23, 2024, 06:02 AM
Evotec SE and Bristol Myers Squibb have announced an expansion of their proteomics partnership, which will now include a new molecular glue-based collaboration. This collaboration begins with a $50 million upfront payment from Bristol Myers Squibb to Evotec. The partnership aims to build a molecular glue-based pipeline, leveraging the success of previous deals between the two companies. The new collaboration focuses on non-protac degraders.
View original story
Similar markets
1 therapy • 25%
2 therapies • 25%
3 therapies • 25%
More than 3 therapies • 25%
1-3 drugs/vaccines • 25%
4-6 drugs/vaccines • 25%
7-9 drugs/vaccines • 25%
10 drugs/vaccines • 25%
More than 3 new drugs • 25%
2-3 new drugs • 25%
1 new drug • 25%
No new drugs • 25%
None • 25%
1-3 targets • 25%
4-6 targets • 25%
More than 6 targets • 25%
0 new partnerships • 25%
1-2 new partnerships • 25%
3-4 new partnerships • 25%
5 or more new partnerships • 25%
0-1 • 25%
2-3 • 25%
4-5 • 25%
More than 5 • 25%
1 new acquisition • 25%
2 new acquisitions • 25%
3 new acquisitions • 25%
4 or more new acquisitions • 25%
No new partnerships • 33%
1-2 new partnerships • 33%
More than 2 new partnerships • 33%
0-1 projects • 25%
2-3 projects • 25%
4-5 projects • 25%
More than 5 projects • 25%
0 to 2 • 25%
3 to 5 • 25%
6 to 8 • 25%
More than 8 • 25%
3 or more • 25%
2 • 25%
1 • 25%
None • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%